Bone Substitutes Outcomes - Post Market Follow-up

Inclusion Criteria:

• Be 18 years or older.

• Be willing to sign an informed consent approved by IRB or EC (where applicable) ornot being opposed to the use of their clinical data in the study (France) and o For prospective inclusion:

• Be considered for a surgery where bone filling with one of the TEKNIMED bonesubstitutes comprised in this study is needed and intended to be used according tothe IFU. o For retrospective inclusion:

• Have undergone a surgery with a TEKNIMED bone substitute used according to the IFU,between the 1st January 2015 and the date of the site initiation visit

• Be informed of the study and not being opposed to the use of their clinical data inthe study (France) or be willing to sign an informed consent (where applicable)during the first follow-up visit following the site initiation.

Exclusion Criteria:

Patients presenting one of the following conditions will not be included:

• Under trusteeship or guardianship

• Pregnancy or breast-feeding women

According to contraindications per IFU:

• Procedures other than those stated in the INDICATIONS section

• Patients susceptible to allergic reactions to the product components.

CERAFORM®, TRIHA+®:

• Treatment of large bone defects which could impact the stability of bone structure without implementing a mechanical stabilisation system (such as plate(s), screw(s), nail(s), cage(s))

NANOGEL®:

• Use in vertebroplasty procedures

• Subcutaneous use